{"name":"Aptevo Therapeutics","slug":"aptevo-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":3114000,"revenueGrowth":0,"grossMargin":0,"rdSpend":14540000,"netIncome":-25967000,"cash":27194000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPVDZFdUc5OWowdWFSdTU2Rm05LUthbmE2V2N6VTFHNmJHNmV6LWxMYWMxUXZEeGs3NzU2ZmxWeVd1c2RKZ0FhOVJ6NFoweE9rVi1FTW5FTFhwbU5JOFlsLWNzaUFrMHowWjV3dDYzdUN3THpiVVJGd0JNNjIzMDVWOGJCY0JLNkFSVFRad1BJeURaeG1XTEJGbWZTOVNXTi1yb3NYb0x3YUxudlRySU5OUHg3Vlo4LUxvSGtEdFEtNjhvT2hIbXhz?oc=5","date":"2026-03-19","type":"pipeline","source":"ACCESS Newswire","summary":"Aptevo to Participate in March 2026 Conferences - ACCESS Newswire","headline":"Aptevo to Participate in March 2026 Conferences","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNYzM3T2ZuNUQ5Ni16VVZnMkYwZGNON2REUGFUVW5oVVVVd1VQc211b0FzN202OUN4b2ZQTUs4d1ZFcUdjVGpDZmJfSE03LUlZWm5wT0pldmNyRlpHY3g4Q3k2NDNnbEhWNjFkeUswWlRrWW9fQk5YYzFrVEtSaHlmeG9GT055UUVkdGZ5TlZqeWdYNkdMWkpkd3lHdWVPZy1XaEFEbW5MS1NKZHBsUklFeG1ITWxPU3o5VG9lZFJR?oc=5","date":"2026-03-10","type":"trial","source":"Stock Titan","summary":"Leukemia trial: 86% of older patients benefit, no cytokine release syndrome - Stock Titan","headline":"Leukemia trial: 86% of older patients benefit, no cytokine release syndrome","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUU5nQVZCZVh3Y0NMZThua2pLMXpXTzZoLUNDekpfY08tcnFremgzQ2otM0VSU1NPOXlVS01BNmlJbEY0WmpSNHVwWkFZQXRmWXJtOWx5bnRBYW5hbnNDeTlvZlZGWVR6Y0dNZXlSYWZfUkt3czhYakVGenhWaWI5TGRuZXI2NG1Na3ZJUGdkdnB0LUlqdHNVbTRsNFRlWnZpNXlIVUM4ZWU?oc=5","date":"2025-12-21","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Wall Street’s Leaders and Laggards of 2025 - Genetic Engineering and Biotechnology News","headline":"StockWatch: Wall Street’s Leaders and Laggards of 2025","sentiment":"neutral"},{"date":"2025-12-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQZy00SE9iTkd2emdtaXZ5OG1SWGM5NGxxdkw2NG9qMTJqajc0VHVLZkNsSEhiQm50cGJwWVNqN2E1aFhfWm5NRE5UbGZBWVJkSG5Ea2JRRTRHSGZOX25GVEZoY0tQZzkzQXlITEtwcE5oX3lGRGpHSTZLcHJMT19RTGU5T0lfcHZnOWlld2tjM3VRd09XWkRVUXA3aDN4cFo1YVNIYjY3QWFhcGhXWHB4SVN3UHJZeEhsc3JDdVoybE11OG1zRnRNRk1QczdCSDNjeDZkNF94UGpNcDQzZHp2S3ByLXF0SW9kVnZ5QQ?oc=5","date":"2025-10-07","type":"regulatory","source":"Benzinga","summary":"Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPZlYwaTdYRFVzQUlCRzhvczJtejEyT3k4RUdmbVo1VDJJMHotWkxTUm1xZXVHaGZ6MXRJTFdYV2Y3bVJNWkluVGlqcFV3dkw3TUxEbFZpS3E0LU5MWENKOTBuNVppRloxbFNZSFMzTDVIR01tcm5xcjBrQzh2RjlvV0t1VHNFUGZTRk5JaG1MNDVEYl9iaEJOSDJrSWJXal9GRF9ldlk2aFNlTXZzbmJham9PcGRUT2Y5cnc?oc=5","date":"2025-09-17","type":"pipeline","source":"Markets Mojo","summary":"Aptevo Therapeutics Stock Plummets to New 52-Week Low of $1.32 - Markets Mojo","headline":"Aptevo Therapeutics Stock Plummets to New 52-Week Low of $1.32","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRXYyU1d6NXpfVV83NUczU0ZBSEstcXNnWHhoM01pTDV6R3diX09jYkJXZUxuX1RGbEZyX01uRlBaUkd4alJXakRfS2V1RDFuWVZmQU1OUDJXdjVPWWpMVnBGX0VzTGlyYVd4UFp4ZGZNbzdSMmRfQV9NSkswTl9kVTlOOS10M1l0YTh3SEdzdkFhZUozNGhFbjRyOEhPT3FFSS0zaXgtVkxsalczLTQzNkFxRkFTUS1HSWs0VHhDdWJHNVZiSXBHeDZaZHZpMGJ6X0FZSklMSjdhclFoNVhxMkFjM01hdzJxQkhKQVJnSWw5bzNQOXBZMUNR?oc=5","date":"2025-09-16","type":"trial","source":"Stocktwits","summary":"Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort - Stocktwits","headline":"Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9USFh0U3ZNLTRSa2ZRRGpzSUJ4WUo3MUs0OWhaeEJWaHMtcTlFYldfYzBfQlRSaTFUNkxFVlRsNF9nNkhvbExYNlM1SUxtaU83ekdGNUJTSXhrOWt0LWE0Vmp5QlhNcmxK?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Aptevo Therapeutics (APVO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Aptevo Therapeutics (APVO) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":3114000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":3114000,"period":"2022-12-31"},{"value":3114000,"period":"2022-12-31"},{"value":12292000,"period":"2021-12-31"},{"value":12292000,"period":"2021-12-31"},{"value":4309000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":14540000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-25967000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":27194000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}